⁶⁸Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to ¹⁸F-FDG PET/CT.

ABSTRACT: ¹⁸F-FDG PET/CT has some limitations in the evaluation of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL), an indolent B-cell lymphoma that primarily involves the bone marrow. Because there is a high level of chemokine receptor 4 expression in the B cells of WM/LPL patients, we performed a prospective cohort study to evaluate the performance of ⁶⁸Ga-pentixafor, which targets chemokine receptor 4 in WM/LPL, and to compare it with the performance of ¹⁸F-FDG. Methods: Seventeen patients with WM/LPL were recruited. All patients underwent both ⁶⁸Ga-pentixafor PET/CT and ¹⁸F-FDG PET/CT. A positive PET/CT result was defined as the presence of focal lesions with positive PET results or diffuse bone marrow patterns (upta

SUBMITTER: Luo Y 

PROVIDER: S-EPMC6894383 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature